Novel Therapeutic Strategies for Lung Cancer in the Era of Personalized Treatment
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (10 September 2022) | Viewed by 8819
Special Issue Editors
Interests: lung cancer; interventional pulmonology; chemotherapy and immunotherapy
2. Laboratory of Histology-Embryology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
Interests: asthma; lung cancer; biomarkers; airway remodeling
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Lung cancer still remains as the world's leading cause of cancer death. Clinical development of immune checkpoint inhibitors (ICIs) has dramatically changed the prognosis of patients with non-small cell lung cancer. Of note, for the first time in 30 years, immunotherapy has also shown a survival benefit in patients with small cell lung cancer. Despite these advantages, the identification of reliable biomarkers is critical in efforts to further identify a subset of patients that may benefit from immunotherapy. Moreover, a combination of ICIs with other treatments is now under investigation to extend their efficacy in lung cancer patients.
Thus, the aim of this Special Issue is to highlight recent studies on therapeutic strategies and biomarker evaluation in lung cancer.
Dr. Konstantinos Porpodis
Dr. Kelly Domvri
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung cancer
- biomarkers
- immunotherapy
- targeted therapies
- personalized treatment
- treatment combinations
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.